دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?
John J.V. McMurray, Milton Packer
doi : 10.1161/CIRCULATIONAHA.120.052926
Circulation. 2021 | Volume 143, Issue 9: 875–877
Neurocognitive Dysfunction and Smaller Brain Volumes in Adolescents and Adults With a Fontan Circulation
Charlotte E. Verrall, Joseph Y.M. Yang, Jian Chen, Adrian Schembri, Yves d’Udekem, Diana Zannino, Nadine A. Kasparian, Karin du Plessis, Stuart M. Grieve, Thomas Welton, Belinda Barton, Thomas L. Gentles, David S. Celermajer, Chantal Attard, Kathryn Rice, Julian Ayer, Simone Mandelstam, David S. Winlaw, Mark T. Mackay, Rachael Cordina
doi : 10.1161/CIRCULATIONAHA.120.048202
Circulation. 2021 | Volume 143, Issue 9: 878–891
Neurocognitive outcomes beyond childhood in people with a Fontan circulation are not well defined. This study aimed to investigate neurocognitive functioning in adolescents and adults with a Fontan circulation and associations with structural brain injury, brain volumetry, and postnatal clinical factors.
A Life-Course Approach to the Neurodevelopmental Trajectory of Congenital Heart Disease
Mike Seed, Steven P. Miller
doi : 10.1161/CIRCULATIONAHA.120.052436
Circulation. 2021 | Volume 143, Issue 9: 892–894
Linear and Nonlinear Mendelian Randomization Analyses of the Association Between Diastolic Blood Pressure and Cardiovascular Events
Marios Arvanitis, Guanghao Qi, Deepak L. Bhatt, Wendy S. Post, Nilanjan Chatterjee, Alexis Battle, John W. McEvoy
doi : 10.1161/CIRCULATIONAHA.120.049819
Circulation. 2021 | Volume 143, Issue 9: 895–906
Recent clinical guidelines support intensive blood pressure treatment targets. However, observational data suggest that excessive diastolic blood pressure (DBP) lowering might increase the risk of myocardial infarction (MI), reflecting a J- or U-shaped relationship.
Temporal Changes in Secondary Prevention and Cardiovascular Outcomes After Revascularization for Peripheral Arterial Disease in Denmark
Mette S?gaard, Peter Br?nnum Nielsen, Flemming Skj?th, Nikolaj Eldrup, Torben Bjerregaard Larsen
doi : 10.1161/CIRCULATIONAHA.120.047994
Circulation. 2021 | Volume 143, Issue 9: 907–920
Patients with peripheral arterial disease (PAD) are at increased risk of cardiovascular morbidity and mortality. Medical prevention with antithrombotic and statin therapies is a mainstay of treatment to prevent adverse outcomes; nevertheless, patients with PAD are often undertreated. This study describes the temporal changes in medical prevention and adverse outcomes in a national cohort of patients with symptomatic PAD after revascularization.
Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis
Mark Trinder, Yanan Wang, Christian M. Madsen, Tatjana Ponomarev, Lubos Bohunek, Brendan A. Daisely, HyeJin Julia Kong, Lisanne L. Blauw, B?rge G. Nordestgaard, Anne Tybj?rg-Hansen, Mark M. Wurfel, James A. Russell, Keith R. Walley, Patrick C.N. Rensen, John H. Boyd, Liam R. Brunham
doi : 10.1161/CIRCULATIONAHA.120.048568
Circulation. 2021 | Volume 143, Issue 9: 921–934
The high-density lipoprotein hypothesis of atherosclerosis has been challenged by clinical trials of cholesteryl ester transfer protein (CETP) inhibitors, which failed to show significant reductions in cardiovascular events. Plasma levels of high-density lipoprotein cholesterol (HDL-C) decline drastically during sepsis, and this phenomenon is explained, in part, by the activity of CETP, a major determinant of plasma HDL-C levels. We tested the hypothesis that genetic or pharmacological inhibition of CETP would preserve high-density lipoprotein levels and decrease mortality in clinical cohorts and animal models of sepsis.
Mapping the Endothelial Cell S-Sulfhydrome Highlights the Crucial Role of Integrin Sulfhydration in Vascular Function
Sofia-Iris Bibli, Jiong Hu, Mario Looso, Andreas Weigert, Corina Ratiu, Janina Wittig, Maria Kyriaki Drekolia, Lukas Tombor, Voahanginirina Randriamboavonjy, Matthias S. Leisegang, Philipp Goymann, Fredy Delgado Lagos, Beate Fisslthaler, Sven Zukunft, Anastasia Kyselova, Alberto Fernando Oliveira Justo, Juliana Heidler, Diamantis Tsilimigras, Ralf P. Brandes, Stefanie Dimmeler, Andreas Papapetropoulos, Stefan Knapp, Stefan Offermanns, Ilka Wittig, Stephen L. Nishimura, Fragiska Sigala, Ingrid Fleming
doi : 10.1161/CIRCULATIONAHA.120.051877
Circulation. 2021 | Volume 143, Issue 9: 935–948
In vascular endothelial cells, cysteine metabolism by the cystathionine ? lyase (CSE), generates hydrogen sulfide–related sulfane sulfur compounds (H2Sn), that exert their biological actions via cysteine S-sulfhydration of target proteins. This study set out to map the “S-sulfhydrome” (ie, the spectrum of proteins targeted by H2Sn) in human endothelial cells.
Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials
Ravi B. Patel, Jozine M. Ter Maaten, Jo?o Pedro Ferreira, Finnian R. McCausland, Sanjiv J. Shah, Patrick Rossignol, Scott D. Solomon, Muthiah Vaduganathan, Milton Packer, Aliza Thompson, Norman Stockbridge, Faiez Zannad
doi : 10.1161/CIRCULATIONAHA.120.049514
Circulation. 2021 | Volume 143, Issue 9: 949–958
Patients with chronic cardiovascular or metabolic diseases, including diabetes, hypertension, obesity, and heart failure, often have comorbid kidney disease. Long-term outcomes are worse in the setting of both cardiac and kidney disease compared with either disease in isolation. In addition, the clinical presentations of certain acute cardiovascular events (such as heart failure) and worsening kidney function overlap and may be challenging to distinguish. Recently, certain novel treatments have demonstrated beneficial effects on both cardiac and kidney outcomes. Sodium-glucose cotransporter-2 inhibitors have exhibited concordant risk reduction and clinically important benefits in chronic kidney disease with and without diabetes, diabetes and established cardiovascular disease or multiple atherosclerotic vascular disease risk factors, and heart failure with reduced ejection fraction with and without diabetes. Primary trial results have revealed that sacubitril-valsartan therapy improves cardiovascular outcomes in patients with chronic heart failure with reduced ejection fraction and post hoc analyses suggest favorable kidney effects. A concordant pattern of kidney benefit with sacubitril-valsartan has also been observed in chronic heart failure with preserved ejection fraction. Given the complex interplay between cardiac and kidney disease and the possibility that treatments may show concordant cardio-kidney benefits, there has been recent interest in formally acknowledging, defining, and using composite cardio-kidney outcomes in future cardiovascular trials. This review describes potential challenges in use of such outcomes that should be considered and addressed before their incorporation into such trials.
Hidden in Plain Sight
Sarah Chuzi, FeiLi Kuang, Sadiya S. Khan
doi : 10.1161/CIRCULATIONAHA.120.052825
Circulation. 2021 | Volume 143, Issue 9: 959–964
Reduced Right Ventricular Sarcomere Contractility in Heart Failure With Preserved Ejection Fraction and Severe Obesity
M. Imran Aslam, Virginia S. Hahn, Vivek Jani, Steven Hsu, Kavita Sharma, David A. Kass
doi : 10.1161/CIRCULATIONAHA.120.052414
Circulation. 2021 | Volume 143, Issue 9: 965–967
Feasibility and Performance of Noninvasive Ultrasound Therapy in Patients With Severe Symptomatic Aortic Valve Stenosis
Emmanuel Messas, Alexander IJsselmuiden, Guillaume Goudot, Selina Vlieger, Samuel Zarka, Etienne Puymirat, Bernard Cholley, Christian Spaulding, Albert A. Hagège, Eloi Marijon, Mickael Tanter, Benjamin Bertrand, Mathieu C. Rémond, Robin Penot, B. Ren, Peter den Heijer, Mathieu Pernot, René Spaargaren
doi : 10.1161/CIRCULATIONAHA.120.050672
Circulation. 2021 | Volume 143, Issue 9: 968–970
COVID-19 at 1 Year
Mitchell S.V. Elkind, Robert A. Harrington, Donald M. Lloyd-Jones
doi : 10.1161/CIRCULATIONAHA.120.053439
Circulation. 2021 | Volume 143, Issue 9: e746–e748
Letter by Vazgiourakis et al Regarding Article, “Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study”
Vasileios Vazgiourakis, George E. Zakynthinos, Vasiliki Tsolaki
doi : 10.1161/CIRCULATIONAHA.120.049322
Circulation. 2021 | Volume 143, Issue 9: e749–e750
Letter by Carrizales-Sep?lveda et al Regarding Article, “Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study”
Edgar Francisco Carrizales-Sep?lveda, Raymundo Vera-Pineda, Ramiro Flores-Ram?rez
doi : 10.1161/CIRCULATIONAHA.120.049435
Circulation. 2021 | Volume 143, Issue 9: e751–e752
Response by Szekely et al to Letters Regarding Article, “Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study”
Yishay Szekely, Yael Lichter, Yan Topilsky
doi : 10.1161/CIRCULATIONAHA.120.051635
Circulation. 2021 | Volume 143, Issue 9: e753–e754
Expression of Concern: Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Bypass Grafting (POPular CABG): A Randomized Double-Blind, Placebo-Controlled Trial
doi : 10.1161/CIR.0000000000000962
Circulation. 2021 | Volume 143, Issue 9: e755
